1 hr 31 min
How Weight-Loss Drugs Could Impact U.S. Healthcare and Food. Plus, the Biggest Problems With GLP1s. Plain English with Derek Thompson
-
- News Commentary
Today’s episode is our second in a series on the weight-loss drug revolution of the last two years.
On Tuesday, we talked to endocrinologist Beverly Tchang about the science of glucagon like peptide 1 receptor agonists—also known as GLP1s, also known as Ozempic, Wegovy, Moujargo, and Zepbound. If you haven’t listened to that show, I think you’ll feel safe and entertained within the bounds of this episode. But if you want to know more about how these drugs work, their effect on insulin and glucose and the brain’s reward center, or the questions they raise about obesity and the nature of willpower and free will, I’d encourage you to queue up that show. Today, in Part 2, we have two guests: Zach Reitano is the CEO and cofounder of the telehealth platform Ro. He is here for a couple reasons. He has a bird’s-eye view of the GLP1 marketplace, the rise in demand, the supply chain, the economics of pricing and insurance. He’s also written several revelatory essays, pulling in research from think tanks, medical experts, and investment banks, that have helped shape my understanding of these drugs and the effect they could have on the population and the economy. Our second guest is Dr. Robert Lustig, an endocrinologist who spent years as a pediatrician and researcher at the University of California-San Francisco. As you’ll hear, he is much less optimistic about the ability of these drugs to revolutionize obesity medication in America.
If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.
Host: Derek Thompson
Guests: Zach Reitano & Robert Lustig
Producer: Devon Baroldi
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Today’s episode is our second in a series on the weight-loss drug revolution of the last two years.
On Tuesday, we talked to endocrinologist Beverly Tchang about the science of glucagon like peptide 1 receptor agonists—also known as GLP1s, also known as Ozempic, Wegovy, Moujargo, and Zepbound. If you haven’t listened to that show, I think you’ll feel safe and entertained within the bounds of this episode. But if you want to know more about how these drugs work, their effect on insulin and glucose and the brain’s reward center, or the questions they raise about obesity and the nature of willpower and free will, I’d encourage you to queue up that show. Today, in Part 2, we have two guests: Zach Reitano is the CEO and cofounder of the telehealth platform Ro. He is here for a couple reasons. He has a bird’s-eye view of the GLP1 marketplace, the rise in demand, the supply chain, the economics of pricing and insurance. He’s also written several revelatory essays, pulling in research from think tanks, medical experts, and investment banks, that have helped shape my understanding of these drugs and the effect they could have on the population and the economy. Our second guest is Dr. Robert Lustig, an endocrinologist who spent years as a pediatrician and researcher at the University of California-San Francisco. As you’ll hear, he is much less optimistic about the ability of these drugs to revolutionize obesity medication in America.
If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.
Host: Derek Thompson
Guests: Zach Reitano & Robert Lustig
Producer: Devon Baroldi
Learn more about your ad choices. Visit podcastchoices.com/adchoices
1 hr 31 min